IBI308
Phase 3Small molecule
Innovent Biologics (Suzhou) Co. Ltd.IBI308 is one of 97 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.
3
Indications
9
Total Trials
1
Active Trials
96
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 3
Tuoyi
SSun Yat-sen University
Phase 3
Incomplete Freund's Adjuvant
EEastern Cooperative Oncology Group
Phase 3
Epacadostat
IncytePhase 3
Intismeran Autogene
Merck & Co.Phase 3
Masitinib
AAB Science
Phase 3
Investigator's Choice
PfizerPhase 3
IBI308
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
Intron a
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Anti-PD-1 Antibody1 trial
Melanoma1 trial
Hepatocellular Carcinoma1 trial
4 more indications
Advanced Solid Tumors1 trial
Esophageal Squamous Cell Carcinoma1 trial
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IBI308. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details